GnRH receptors (GnRH-Rs
G nRH REGULATES THE secretion of LH and FSH from
the pituitary (1) . GnRH-stimulated gonadotropin secretion can be blocked with antagonists or mimicked by agonists, but in the latter case sustained stimulation causes desensitization. Thus, both agonists and antagonists ultimately reduce the circulating levels of gonadotropins and gonadal steroids. This effect, termed medical castration, is exploited to treat sex hormone-dependent neoplasms such of those of the prostate, ovary, endometrium, or breast (2, 3) . At the pituitary, GnRH acts via G protein-coupled receptors (GPCRs) that act via G q/11 to stimulate PLC, thereby causing an IP 3 -mediated mobilization of Ca 2ϩ from intracellular stores. This Ca 2ϩ mobilization along with the entry of Ca 2ϩ across the plasma membrane and the concomitant activation of PKC, are thought to mediate GnRH-stimulated gonadotropin secretion (1, 4 -6) . GnRH also activates four MAPK signaling modules in pituitary cells, and PKC plays a key role in mediating such activation (5, (7) (8) (9) . Although there is no direct evidence that GnRH can activate any G protein other than G q/11 in gonadotrophs or ␣T3-1 cells, it is apparently able to do so in other cell types. In heterologous expression systems, GnRH has been shown to stimulate cAMP accumulation via GnRH receptors (GnRH-Rs) expressed stably in GGH 3 cells (10) or transiently in COS-7 (11) and Sf9 cells (12) . Interestingly, the coupling of GnRH-Rs to adenylyl cyclase is apparently density dependent in GGH 3 cells, where GnRHstimulated cAMP accumulation increases as GnRH-R number is reduced (13) . Accordingly, GnRH-R signaling may be qualitatively and quantitatively dependent upon cellular context and receptor density. GnRH-Rs are also found (often along with GnRH) in some mammary, prostatic, endometrial, and ovarian cancers (3, 14 -17) . Interest in these extrapituitary GnRH-Rs stems primarily from the fact that GnRH analogs (or cytotoxic derivatives of GnRH analogs) can inhibit the proliferation of cell lines derived from such cancers and that direct antiproliferative effects on cancer cells may therefore contribute to therapeutic effects of GnRH analogs in cancer treatment (14 -18) . Although GnRH-R transcripts detected in breast and ovarian cancers are identical to those in pituitary (19) , the receptors may differ functionally. In binding studies (16) pituitary GnRH-Rs have high affinity for agonists such as buserelin (nanomolar K d values), whereas the majority of GnRH-Rs in extrapituitary sites have low affinity (micromolar K d values). There are also apparent differences in signaling. Whereas GnRH-Rs in gonadotropes are positively coupled to PLC and MAPK activation, those in ovarian and Abbreviations: Ad EGFP, Adenovirus expressing enhanced green fluorescent protein; Ad GnRH-R, recombinant adenovirus-expressing GnRH-R; B max , binding capacity; [Ca 2ϩ ] i , cytosolic Ca 2ϩ concentration; cGnRH-II, chicken GnRH-II; EGF, epidermal growth factor; EGFP, enhanced green fluorescent protein; GnRH-R, GnRH receptor; GPCR, G protein-coupled receptor; moi, multiplicity of infection; MTT, 3-[4,5-dimethylthiazol-2yl]-diphenyltetrazolium bromide; PSS, physiological salt solution.
endometrial cancer cell lines appear not to activate PLC and, in the presence of epidermal growth factor (EGF), actually inhibit ERK phosphorylation (3, 16) . Similar inhibition was observed in prostatic cancer cell lines (20) , and it has been suggested that a G I -mediated activation of protein phosphatase activity underlies the antiproliferative effect of GnRH in human cancer cells (21, 22) . Moreover, the antiproliferative effects of GnRH-R agonists in some cancer cell models can be mimicked by analogs such as cetrorelix, which are competitive antagonists at pituitary GnRH-Rs (16) , leading to the suggestion that the agonist/antagonist dichotomy established for pituitary GnRH-Rs may not apply in extrapituitary sites (23) . This issue is controversial, however, because endogenously produced GnRH may also stimulate the proliferation of some cancer cell lines, so that antiproliferative effects of endogenous agonists and antagonists could reflect GnRH-R down-regulation and blockade, respectively (24) .
Until recently it was generally thought that any given GPCR would have one active conformation and couple to one G protein-coupled (e.g. G s or G q ) with one effector (e.g. PLC or adenylyl cyclase), but recent studies have revealed diversity of coupling for a number of receptors. Some GPCRs act via multiple G proteins to control multiple effectors or to directly activate proteins other than heterotrimeric G proteins, and GPCR function can be dramatically altered by accessory proteins (25) (26) (27) . The activation of multiple effector proteins by a single receptor can reflect the existence of multiple active conformations preferentially coupled to distinct effectors, in which case specific ligands may preferentially stabilize specific active conformations such that different ligands can target signaling to distinct effectors (28) . Accordingly, ligand specificity and signaling can depend not only on GPCR structure, but also on receptor number, cell type, and ligand, such that the reported differences between pituitary and extrapituitary receptors could reflect an extreme degree of context dependence by this receptor. If this is the case, GnRH-Rs expressed exogenously in extrapituitary sites would be expected to display functional characteristics distinct from those of GnRH-Rs in pituitary gonadotropes. To test this possibility we have developed recombinant adenovirus-expressing GnRH-Rs (Ad GnRHs) and used these to express receptors in a human breast cancerderived cell line at a density that would be physiological for pituitary GnRH-Rs. We show that these receptors are essentially indistinguishable (in terms of binding, signaling, and agonist/antagonist discrimination) from those in pituitary cells. This procedure also facilitates a pronounced antiproliferative effect of GnRH agonists on these cells, implying that GnRH-R number is limiting for this direct antiproliferative effect and that manipulation increasing GnRH-R number in breast cancer (for example) may therefore increase the effectiveness of direct GnRH-R-targeted therapy. 
Materials and Methods

Materials and cell culture
Generation of recombinant adenovirus
Recombinant, E1-deleted adenovirus-expressing sheep GnRH receptors (Ad GnRH-R) were prepared as previously described (29 -31) . Briefly, DNA encoding sheep GnRH-R was excised from pcDNA1/Amp plasmids (Invitrogen, Nu Leek, The Netherlands), and the insert was ligated into an identically digested (BamHI/XbaI) pXCXCMV shuttle vector. After transformation and growth in Escherichia coli, this was purified and used for homologous recombination with the pJM17vector after CaPO 4 transfection of HEK-293 cells (Microbix Systems, Inc., Toronto, Canada). The cells were overlayed in medium with 0.5% agarose, and individual recombinant Ad plaques were amplified. After sequence confirmation, Ad stocks were expanded by infection of HEK-293 cells, followed by extraction and CsCl 2 gradient purification. Viral titer was determined using a plaque assay and is reported as multiplicity of infection (moi) where an moi of 1 represents 1 plaque forming unit/ plated cell. In some experiments control Ad (empty Ad lacking the GnRH-R insert) was used, and in others transfection efficiency was assessed using an Ad expressing enhanced green fluorescent protein (Ad EGFP). These had been previously prepared (31 4 , 5 mm NaHCO 3 , 10 mm glucose, 0.1% BSA, and 10 mm HEPES, pH 7.4), each well was stimulated with 200 -250 l PSS containing 10 mm LiCl and the indicated concentration of stimulatory peptide. The stimuli were terminated by adding 1 ml water at 95 C. IPs were then extracted and separated from free [ 3 H]inositol using anion exchange chromatography (31, 32) . In preliminary experiments in which cells were stimulated for 5-60 min with 0 or 10 Ϫ7 m GnRH in medium with 10 mm LiCl, GnRH-stimulated [ 3 H]IP accumulation remained approximately linear for 30 -40 min. Accordingly, a 30-min stimulation time was used for all experiments shown here. For video imaging, fura-2-loaded cells were loaded for 30 min in 1 ml PSS containing 2 m fura-2 (33). Image capture was performed within 10 -25 min of loading at 37 C in approximately 500 l PSS or in Ca 2ϩ -free PSS (containing 250 m EGTA instead of CaCl 2 ) using MagiCal hardware and Tardis software from Applied Imaging (Newcastle-upon-Tyne, UK) and a Nikon Diaphot microscope (Melville, NY). The cells were excited alternately at 340 and 380 nm, and emitted light was collected at 510 nm. The ratio of fluorescence at 340 and 380 nm was calculated on a pixel by pixel basis and used to determine the Ca 2ϩ concentration, assuming a dissociation constant of 225 nm for fura-2 and Ca 2ϩ . Calibration was performed as previously described (33) .
Radioligand binding
GnRH-R expression was assessed using whole cell binding assays in which approximately 50,000 cells were incubated at 21 C in 100 l PSS containing 1 mg/ml bacitracin with approximately 10 Ϫ10 m [ 125 I]buserelin (a high affinity GnRH receptor agonist) and 0 or 10 Ϫ11 -10 Ϫ5 m unlabeled competitor. Free and bound peptide were separated by centrifugation through oil (31, 32) 
MAPK activation
MAPK activation was measured using standard techniques (31) . Briefly, MCF-7 cells were plated in 60-mm dishes at 300,000 cells/dish and infected at moi values between 50 -100. After 48 h they were stimulated (see below) before being washed twice in ice-cold PBS and then lysed on ice for 10 min in 400 l extraction buffer [10 mm Tris (pH 7.6), 5 mm EDTA, 1 mm EGTA, 50 mm NaCl, 30 mm Na ϩ pyrophosphate, 50 mm NaF, 1 mm dithiothreitol, 100 m Na ϩ orthovanadate, 1% Triton X-100, 1 mm phenylmethylsulfonylfluoride, 10 g/ml antipain, 2 g/ml leupeptin, and 2 g/ml pepstatin]. The samples were then centrifuged (13,000 ϫ g, 10 min, 4 C), and 40 l supernatant were boiled with 40 l sample buffer. Proteins were separated by SDS-PAGE (8% gel), transferred to polyvinylidene difluoride membrane, and blocked with 5% milk/Tris-buffered saline/Tween. ERK2 was detected with anti-ERK2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and visualized using enhanced chemiluminescence (Amersham Pharmacia Biotech, Little Chalfont, UK). The appearance of a retarded (phosphorylated) band was taken as evidence of ERK2 activation. This was quantified by densitometry, and the intensity of the phosphorylated band was normalized as a percentage of the summed densities of both (providing an internally controlled measure of ERK2 activation).
[ 3 H]Thymidine incorporation and MTT assays
Incorporation of [
3 H]thymidine into newly synthesized DNA was used as an index of cell proliferation (35, 36) . Cells were plated in 96-well plates in 250 l DMEM with 10% FCS at a density of 5000 cells/ml. After 24 h they were transferred to DMEM containing 1% FCS and incubated with test adenovirus at varied moi (3-300, or 0 in control cells). After 6 h the cells were transferred to fresh DMEM (1% FCS) and incubated for approximately 24 h before addition of test peptides. After a further 6 or 7 d, 0.5 Ci [ 3 H]thymidine was added to each well and left to incorporate for 4 h. The cells were incubated in 100 l trypsin/EDTA at 37 C for 30 min. The cells were then frozen and thawed, and incorporated [
3 H]thymidine was collected on A filter papers (Wallac, Inc., Gaithersburg, MD) using a 96-well harvester and quantified by ␤-counting (l450 Microbeta Plus, Wallac, Inc.). In some experiments the rate of MTT hydrolysis was also determined by incubating cells cultured in 96-well plates for 4 h at 37 C in culture medium with 0.5 mg/ml MTT (Sigma). The incubation medium was then replaced with 50 l acidified isopropanol (10 mm HCl in isopropanol), and the colored product was quantified by absorbance spectroscopy at 515 nm. Standard curves were also generated by measuring MTT activity in known numbers of cells (5,000 -120,000), enabling calculation of cell number from MTT activity.
Statistical analysis and data presentation
The figures show data from a single representative experiment or the mean Ϯ sem of data pooled from n independent experiments (data normalized as described in the figure legends). Data are typically reported in the text as the mean Ϯ sem, and statistical analysis was performed using two-tailed t tests, accepting P Ͻ 0.05 as statistically significant.
Results
Our first attempts at expression of GnRH-Rs in MCF-7 cells were unsuccessful because of the low transfection efficiency achieved with conventional strategies. When MCF-7 cells were transfected with an EGFP reporter using lipofectin, LipofectAMINE Plus (Life Technologies, Inc.), Fugene (Boehringer Mannheim, Lewes, UK), and CaPO 4 as previously described (31), flow cytometry revealed transfection efficiencies of less than 20% (not shown). In contrast, infection with Ad EGFP yielded a transfection efficiency approaching 100% (at moi values of Ն10) and much higher levels of fluorescence per cell (not shown). We therefore constructed sheep Ad GnRH-R, confirmed the identity of the insert by restriction digestion and sequencing (not shown), and measured cell surface expression of GnRH-Rs after infection of MCF-7 cells with Ad GnRH-R. We were unable to detect specific binding of [ 125 I]buserelin to control (uninfected) MCF-7 cells, but after 2 d of infection with Ad GnRH-R at varied viral titer (moi, 3-300), there was a clear titer-dependent increase in specific binding (Fig. 1) . This binding was blocked in a concentration-dependent manner by unlabeled buserelin, and curve fitting revealed these to be high affinity sites, with K d values of 0.9 -2.0 nm. As the K d was not dependent upon viral titer, B max values were calculated by fitting the curves with the mean K d value of 1.4 nm, and this revealed that increasing the Ad GnRH-R titer from 3 to 300 increased the number of binding sites from 10,000 to 225,000 sites/cell (Fig. 1, inset) . To assess whether these sites were indeed functional receptors, possible activation of PLC was assessed using an [ 3 H]IP accumulation assay. As shown (Fig. 2) 
ulating [
3 H]IP accumulation with the same peptides. As shown (Fig. 3) , all three peptides inhibited binding and stimulated [ 3 H]IP accumulation, with a rank order of potency (buserelinϾGnRHϾcGnRH-II) identical to that for endogenous mammalian GnRH-Rs in pituitary cells (1, 4, 32) and for human and sheep GnRH-Rs expressed using recombinant Ad in ␣T4 pituitary cells (31) (data not shown). Together, these data demonstrate that infection of MCF-7 cells with Ad GnRH-R causes expression of functional GnRH-Rs with fundamental pharmacological characteristics (affinity, potency, and relative potency for ligands in binding and functional assays) indistinguishable from those of mammalian GnRH-Rs in gonadotrophs. Preliminary experiments were also performed using recombinant Ad expressing the human GnRH-R, and although similar results were obtained, higher expression levels were achieved with the Ad-expressing sheep GnRH (not shown). As no major differences are known between the signaling or pharmacological characteristics of these receptors, the sheep GnRH-R was used throughout the following experiments.
We next determined the sensitivity of these (Fig. 5) .
As GnRH and a GnRH-R antagonist both inhibit EGFstimulated MAPK signaling in human ovarian and endometrial cancer cell lines (16), we next explored this possibility in MCF-7 cells infected with Ad GnRH-R. As shown (Fig. 6 , upper panel), GnRH and EGF both caused a rapid activation of MAPK signaling (as measured by increased phosphorylation of ERK2) in Ad GnRH-R MCF-7 cells. The responses to GnRH and EGF had similar time courses (both maximal at ϳ15 min, with a gradual reduction thereafter), although the response to EGF was greater than that to GnRH. Using a single time point (15 min; Fig. 6, lower panel) , we found that cetrorelix failed to stimulate MAPK in control or Ad GnRH- R-infected cells, and that the stimulatory effect of GnRH was only observed in Ad GnRH-R-infected cells. Moreover, the stimulatory effect of EGF was similar in control and Ad GnRH-R-infected cells and was not inhibited by GnRH or cetrorelix.
As GnRH analogs can directly inhibit the proliferation of some breast cancer cell lines, we examined possible peptide effects on [ 3 H]thymidine incorporation and MTT hydrolysis in Ad GnRH-R-infected MCF-7 cells. As shown (Fig. 7) , GnRH caused a dose-dependent inhibition of [ 3 H]thymidine incorporation and MTT activity in MCF-7 cells infected with Ad GnRH-R at an moi of 100, but failed to inhibit either in control cells (below and unpublished data). As [ 3 H]thymidine incorporation was assessed during a brief incubation after 5-6 d of exposure to the tested peptide, its inhibition could reflect a reduction in proportional entry into the S phase at the time of [ 3 H]thymidine exposure and/or a reduction in proliferation or survival of cells during the preceding 5-6 d. Preliminary experiments, using release of lactate dehydrogenase as a measure of cytotoxicity, revealed no cytotoxic effect of GnRH (10 Ϫ11 -10 Ϫ6 m) in control or Ad GnRH-R-infected cells. As the inhibition of [ 3 H]thymidine incorporation is more pronounced than the reduction in MTT activity (which is proportional to cell number), GnRH-R activation apparently reduced the rate of DNA synthesis (per cell), thereby reducing cell number.
To test for dependence on the transfected receptors, we next assessed GnRH effects on [ 3 H]thymidine incorporation in control and Ad GnRH-R-infected cells. As shown (Fig. 8,  upper panel) , there was no inhibitory effect of GnRH in control 
FIG. 5. Effects of GnRH, antide, and cetrorelix on [
3 H]IP accumulation in MCF-7 cells infected with Ad GnRH-R. MCF-7 cells were cultured, infected, and treated exactly as described in Fig. 2 , except that the stimulation was with 0 or 10 Ϫ8 M GnRH in the presence or absence of 10 Ϫ6 M antide or cetrorelix, as indicated. For these experiments the antagonist was added 5 min before GnRH, and the figure shows data pooled from four separate experiments after normalization as a percentage of the response to GnRH alone.
FIG. 6. Effects of EGF, GnRH
, and cetrorelix on MAPK in MCF-7 cells. Activation of the ERK1/ERK2 MAPK signaling cascade was assessed by Western blotting to detect and distinguish unphosphorylated and phosphorylated ERK2 by the retarded mobility of the latter in SDS-PAGE gels. Upper panel, The time course of ERK2 activation was assessed by stimulating Ad GnRH-R-infected MCF-7 cells for 5-60 min with 10 Ϫ7 M EGF (F), 10 Ϫ7 M GnRH (OE), or no additional stimulus (E; controls at 0 and 30 min), as indicated. The inset shows the gel from a single representative experiment, and the main panel shows data pooled from three experiments (mean Ϯ SEM) after densitometry and normalization of the P-ERK2 band as a percentage of the total ERK (P-ERK2 plus ERK2). Lower panel, Effects of GnRH (10 Ϫ7 M) and cetrorelix (10 Ϫ7 M) were assessed in the presence and absence of 10 Ϫ7 M EGF in control (uninfected) cells and in cells infected with Ad GnRH-R (moi, 100) as indicated. Data were pooled from five experiments (as described above) in which GnRH and EGF significantly increased ERK2 phosphorylation (P Ͻ 0.05) whereas cetrorelix did not (P Ͼ 0.05), and neither had any measurable effect in the presence of EGF (P Ͼ 0.05).
uninfected cells or in cells infected with a control (empty) Ad (moi, 100). In contrast, GnRH caused a clear dose-dependent inhibition of [ 3 H]thymidine incorporation in cells infected with Ad GnRH-R. In other experiments (not shown) this inhibitory effect of GnRH was dependent upon Ad titer (25 Ϯ 12%, 81 Ϯ 5%, and 96 Ϯ 1% inhibition by 10 Ϫ7 m GnRH in cells infected at moi values of 30, 100, and 300, respectively). However, the highest Ad titer (moi, 300) inhibited [ 3 H]thymidine incorporation alone (an effect also seen with the control Ad at high titer), so subsequent experiments were performed using an moi of 100 (the highest titer at which the Ad alone did not measurably reduce [ 3 H]thymidine incorporation). Using this Ad titer, comparison of three GnRH receptor agonists revealed that buserelin, GnRH, and cGnRH-II all inhibit [ 3 H]thymidine incorporation into Ad GnRH-Rinfected MCF-7 cells (Fig. 8, lower panel) , although none had any measurable effect in control (uninfected) cells (not shown). The rank order of potency (buserelinϾGnRHϾcGnRH-II) was identical to that observed in the [ (Fig. 9) or into uninfected control cells (not shown). Indeed, when the effect of buserelin was determined in the presence of varied concentrations of antide or cetrorelix, both behaved as competitive inhibitors, shifting the buserelin concentration-response curve rightward in a concentration-dependent manner (Fig. 10) .
Discussion
GnRH or its analogs can exert direct antiproliferative effects on numerous types of steroid-dependent and steroidindependent cancer cells, and for several of these there is good evidence for expression of GnRH-Rs and/or GnRH itself (3, 14 -24) . This has raised the possibility that in addition to reducing gonadal steroid levels (and thereby reducing the steroid-dependent proliferation of tumor cells), GnRH analogs may directly inhibit the proliferation of these cancers, and this direct effect may be further exploited to improve the effectiveness of GnRH analogs. With such a wide range of cell types and model systems explored, it is difficult to generalize about mechanisms of action, but there are three main schools of thought. The first is that GnRH-R activation is inhibitory, such that activation of this receptor slows cancer cell proliferation. From the pharmacological perspective, this is perhaps the most intriguing possibility because of the major differences between GnRH-Rs and response characteristics in pituitary and extrapituitary sites (predominant expression of low affinity receptors that do not discriminate between agonists and antagonists, do not activate PLC or MAPK, and actually inhibit EGF-stimulated MAPK activity in extrapituitary sites). This interpretation essentially requires that the GnRH-R display an extreme example of context or density dependence, begging the question of the molecular determinants of such dependence. The second possibility is that the GnRH-R activation is stimulatory, such that locally produced GnRH supports cancer cell proliferation, and this is prevented by GnRH-R antagonists or by down-regulation with agonists. This provides the simplest explanation for inhibition of cancer cell proliferation by antagonists, where endogenous agonist can be shown to be supporting proliferation. The third possibility is that effects of GnRH analogs are mediated by as yet uncharacterized additional forms of the GnRH-R (or related receptors). Several nonmammalian vertebrates express two or three forms of GnRH-R with distinct pharmacological characteristics (37, 38) , and this may well hold true for mammals, including humans (39, 40) . In this study we sought to address the fundamental question of whether breast cancer cells are capable of expressing exogenous high affinity GnRH-Rs and, if so, whether they differ functionally from GnRH-Rs expressed in the pituitary when expressed at density that would be physiological for gonadotrophs. To do so it was necessary to generate recombinant Ad-expressing GnRH-Rs, because conventional transfection strategies based upon CaPO 4 , Fugene, lipofectin, or Lipofectamine Plus were found to be inefficient (Ͻ20% of cells transfected as revealed by flow cytometry when tested using an EGFP-expressing vector). In contrast, relatively high expression levels were achieved using an EGFPexpressing Ad, and flow cytometry revealed that the vast majority of cells (Ͼ90%) expressed the protein after infection at an moi of 10 or above (31) .
When radioligand binding studies were performed to characterize cell surface GnRH-Rs, we were unable to detect any specific binding of [ 125 I]buserelin. This is in contrast to earlier studies demonstrating antiproliferative effects of GnRH agonists in MCF-7 cells (17, 41), but such effects are not always seen (42) , and it seems likely that the use of different subclones or passages of MCF-7 or the use of different cell culture conditions and bioassays can determine responsiveness to GnRH analogs (42) . In our hands there was no evidence for endogenous GnRH-Rs (as judged by radioligand binding or functional assays) in MCF-7 cells, although we did find endogenous [
125 I]buserelin-binding sites and observe inhibition of proliferation in a second human breast cancer cell line (T47D cells; data not shown). MCF-7 cells from the European Tissue Culture Collection were selected for these studies, specifically to avoid the possible activation of endogenous GnRH-Rs.
Using radioligand binding studies we established that MCF-7 cells, which do not express measurable endogenous GnRH-Rs, are indeed capable of expressing exogenous high affinity GnRH-Rs, and these are essentially indistinguishable from the endogenous GnRH-Rs of pituitary cells and exogenous GnRH-Rs transfected into gonadotroph progenitor cells using recombinant adenovirus (31) . Using [ 3 H]IP accumulation as a measure of PLC activation, we were unable to detect any effect of GnRH in control (uninfected) cells, but
FIG. 8. Effects of GnRH on [
3 H]thymidine incorporation into control and Ad GnRH-R-infected MCF-7 cells. Upper panel, Cells plated at low density in 96-well plates were either not infected (control) or were infected with empty adenovirus or with Ad GnRH-R (each at an moi of 100) and used for assessment of [ 3 H]thymidine incorporation as described in Fig. 7 . The figure shows data pooled from five separate experiments (mean Ϯ SEM; n ϭ 4 -5), each of which had four to six replicate observations. Pooling was achieved by normalizing the data as a percentage of [ 3 H]thymidine incorporation seen in control cells without GnRH. The control value of 9.3 Ϯ 1.6 ϫ 10 3 cpm/well (in cells without Ad or peptide) did not differ (P Ͼ 0.1) from the control value in cells treated with Ad GnRH-R or with empty adenovirus. Lower panel, [ 3 H]Thymidine incorporation was assessed in cells that had been infected with Ad GnRH-R (moi, 100) and cultured as described above, except that the culture medium contained the indicated concentration of GnRH, buserelin, or cGnRH-II. The figure shows data pooled from three separate experiments (mean Ϯ SEM; n ϭ 3), each of which had quadruplicate observations. Pooling was achieved by normalizing the data as a percentage of the observed a clear titer-dependent stimulation in cells infected with Ad GnRH-R. This establishes that the [ 125 I]buserelin binding sites are functional GnRH-Rs and that these high affinity receptors do indeed activate PLC. These receptors were also found to mediate elevation of [Ca 2ϩ ] i , because GnRH had no measurable effect in control cells, but caused a robust and sustained increase in Ad GnRH-R-infected cells. Interestingly, GnRH caused a gradual increase to a sustained plateau level of [Ca 2ϩ ] i in these cells, compared with the characteristic biphasic spike-plateau increase seen with high concentrations of agonist acting at endogenous GnRH-Rs in pituitary cells (43) and with Ad-mediated transfection of GnRH-Rs into gonadotroph progenitor cells (31) . As the spike phase of Ca 2ϩ elevation in pituitary cells is due to IP3-mediated mobilization from intracellular stores, the implication is that in MCF-7 cells such stores are mobilized less rapidly or that the mobilized Ca 2ϩ is cleared less rapidly from the cytoplasm.
Using Ca 2ϩ responses to assess transfection efficiency (31), we found that approximately 90% of cells responded to GnRH at an moi of 10 (not shown), implying that the vast majority of cells express GnRH-Rs at this titer and that the increase in binding caused by increasing titer from 10 -300 therefore reflects an increase in receptors per cell (rather than an increase in the proportion of cells expressing the receptor). This conclusion was reenforced using flow cytometry to assess EGFP expression in cells infected with an Ad EGFP. Again, the vast majority of cells expressed the protein at an moi of 10, and increasing the titer above this increased the amount of protein per cell without measurably altering the proportion of cells expressing the protein (not shown). The dynamic range of receptor number achieved by increasing the Ad GnRH-R titer from 3 to 300 (10,000 to 225,000 sites/ cell) encompasses the range of GnRH-R densities seen in rat pituitaries (ϳ20,000 -75,000 sites/gonadotroph) (44, 45) and ␣T3-1 gonadotrophs (ϳ65,000 -85,000 sites/cell) (35) . Accordingly, manipulation of viral titer provides a simple means of controlling GnRH-R expression in MCF-7 cells at density that would be physiological for gonadotropes.
Activation of these receptors was also found to stimulate MAPK (ERK2 phosphorylation), but not to inhibit EGF-stimulated MAPK activation. Cetrorelix also failed to activate MAPK or influence EGF-stimulated MAPK activity, whereas cetrorelix (and antide) blocked GnRH-stimulated [ 3 H]IP accumulation in Ad GnRH-R-infected cells. Accordingly, these studies performed with GnRH-Rs expressed at a density that would be physiological for pituitary gonadotrophs have not revealed any major difference between the endogenous GnRH-Rs of pituitary cells and exogenous GnRH-Rs in MCF-7 cells. Both have high affinity (nanomolar K d ) for buserelin, both are positively coupled to PLC, Ca 2ϩ mobilization, and MAPK activation, and both show identical ligand specificity, as judged by rank orders of potency and agonist/ antagonist discrimination.
When the possible effects of GnRH analogs on the proliferation MCF-7 cells were investigated using a [ 3 H]thymidine incorporation assay, there was no inhibitory effect of GnRH in control uninfected cells or in cells infected with a control (empty) adenovirus. However, infection of these cells with Ad GnRH-R facilitated a clear concentration-dependent inhibition of [ 3 H]thymidine incorporation. We were unable to detect any cytotoxic effect of GnRH (in control or Ad GnRH-R-infected cells), and the inhibition of [ 3 H]thymidine incorporation was associated with a less marked reduction in cell number. Thus, it appears that GnRH acts via transfected receptors to inhibit proliferation and thereby to reduce cell number. This effect was dependent upon adenovirus titer and was mimicked by buserelin and cGnRH-II, with a rank order of potency (buserelin Ͼ GnRH Ͼ cGnRH-II) identical to that seen for radioligand binding and [ 3 H]IP accumulation. Two further agonists (zoladex and triptorelin) had similar inhibitory effects, with potencies comparable to that of buserelin (data not shown), whereas antide and cetrorelix (both of which are competitive antagonists at pituitary GnRH-Rs) had no such effect. Indeed, both peptides caused competitive inhibition of the response to buserelin (shifting 3 H]thymidine incorporation (on the last day of culture) as described in Fig. 7 , except that the cells were cultured in the presence of buserelin with antide (upper panel) or cetrorelix (lower panel), as indicated. The figure shows data pooled from three separate experiments (mean; n ϭ 3), each of which had quadruplicate observations. SEMs were usually less than 5% and have been omitted for clarity. Pooling was achieved by calculating the percent inhibition of [ 3 H]thymidine incorporation caused by each concentration of buserelin compared with the control rate of incorporation with each concentration of antagonist. These data were generated in parallel with those shown in Fig. 8 , so the control buserelin responses (shown as a percentage of the control in Fig. 8 and as the percent inhibition of the control in Fig. 10 ) are identical. As noted in Fig. 9, 10 Ϫ9 M buserelin reduced MTT activity to 76 Ϯ 2% (from a control value equivalent to ϳ50,000 cells/well). However, no measurable inhibition occurred in the presence of 10 Ϫ7 M cetrorelix or antide (not shown).
the buserelin concentration-response curve rightward in a concentration-dependent manner). None of these peptides measurably altered [ 3 H]thymidine incorporation or MTT activity in control (uninfected) cells.
Together the data presented above establish that direct activation of GnRH-Rs can indeed dramatically inhibit the proliferation of these breast cancer cells and that the pharmacological characteristics of this (exogenous) GnRH-Rmediated response are indistinguishable (in terms of ligand recognition and agonist/antagonist discrimination) from those of pituitary GnRH-Rs. Mechanistically, it is unlikely that this effect is due to inhibition of EGF-stimulated ERK2 phosphorylation, because we saw no such inhibition, and GnRH actually stimulated ERK2 phosphorylation. It is also unlikely to be due to GnRH-R down-regulation, because the antiproliferative effect was increased as receptor number increased. As sustained elevation of [Ca 2ϩ ] i is antiproliferative and/or proapoptotic for many cells, inhibition of [ 3 H]thymidine incorporation may be mediated by Ca 2ϩ mobilization in this model, and this issue is currently under investigation.
It is important to recognize that the conclusions drawn above pertain to the characteristics of GnRH-Rs expressed exogenously in mammary cancer cells and that these do not necessarily reflect the characteristics of any endogenous GnRH-Rs in such cells. It remains conceivable, for example, that accessory proteins dramatically alter the binding and functional characteristics of GnRH-Rs in extrapituitary sites, but that such proteins are present in limiting amounts, and their effects are therefore not evident at high levels of expression of high affinity receptors. Alternatively, it is possible that glyosylation influences GnRH-R function and that glycosylation patterns differ between endogenous receptors expressed at low levels and high level expression of exogenous receptors. The possibility therefore remains that there are genuine functional differences between the endogenous and exogenous GnRH-Rs in mammary cancer cells. Nevertheless, interest in extrapituitary GnRH-Rs stems primarily from their possible use as targets for cancer therapy using agonists, antagonists, or cytotoxic derivatives thereof (14 -24) . Regardless of the mechanism of action, our data unambiguously establish that direct activation of GnRH-Rs can indeed inhibit the proliferation of mammary cancer cells and that receptor number is a limiting determinant of this effect. There is currently considerable interest in the improvement and/or development of endocrine and gene therapies for cancer and in the possible combination of these approaches. It has been suggested, for example, that adenovirus-mediated expression of somatostatin receptors may aid in vivo visualization of transgene expression (46) . It has also been shown that Ad-mediated transfection with type 2 somatostatin receptors can inhibit the growth of pancreatic tumors and improve the effectiveness of somatostatin receptor-targeted therapy in vivo (47) . Such data imply that a vector delivering receptor DNA can be considered as a pro-drug, used to increase the effectiveness of subsequently administered receptor ligand. Although this approach remains highly speculative, the GnRH-R is of particular interest in this context not only because GnRH analogs are already routinely used in hormone-dependent cancer therapy, but also because mammalian GnRH-Rs (unlike all other known GPCRs) do not express C-terminal tails and therefore do not rapidly desensitize (31, 32, 48) .
In summary, we have developed Ad GnRH-Rs and shown that these provide an efficient means of expressing GnRH-Rs in mammary cancer cells. These receptors are indistinguishable from pituitary GnRH-Rs (in terms of ligand recognition, signaling, and agonist/antagonist discrimination) and facilitate a pronounced and potent direct antiproliferative effect of GnRH agonists (but not antagonists) on these cells. As the low number of endogenous high affinity GnRH-Rs may limit the therapeutic effects of GnRH analogs on mammary cancer in vivo, endocrine manipulations or gene therapy used to increase the expression of GnRH-Rs in these cells could increase the effectiveness of subsequent therapies in which the GnRH-R is targeted with agonists or their cytotoxic derivatives.
